Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05886777 · ClinicalTrials.gov registry record · Phase 2
A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV).
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,142
- Enrollment target
NCT05886777 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 1,142 participants.
The verdict
NCT05886777, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,142 participants
- Enrollment target
Study Summary
The purpose of the study is to learn about the safety and effects of a combined vaccine for RSV and COVID-19 when given with a seasonal flu vaccine or when given alone. A combined vaccine will help to reduce the number of vaccinations given when trying to prevent respiratory infections. This study is seeking participants who: * are 65 years of age or older. * are healthy or have well-controlled chronic conditions. * in the past have received at least 3 US-authorized mRNA COVID 19 vaccines, with the most recent vaccine being an updated booster vaccine given at least more than or equal to 150 days before Visit A101 (Day 1). * have not had a flu shot in the last 120 days. * agree to be present for all study visits, procedures, and blood draws. Participants will be involved in this study for 6 months. During this time, participants will have 2 study visits at the study clinic and a 6-month telephone contact.
Interventions
- BIOLOGICAL RSVpreF
- BIOLOGICAL QIV
- BIOLOGICAL Normal Saline Placebo
- BIOLOGICAL Combination [RSVpreF+BNTb162b2]
- BIOLOGICAL Bivalent BNT162b2 (original/Omi BA.4/BA.5)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,142 participants |
| Start Date | 2023-06-05 |
| Est. Completion | 2024-01-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05886777
The ClinicalTrials.gov registry entry for NCT05886777 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,142 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which RSVpreF is the first listed.
NCT05886777 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05886777 about?
NCT05886777 is a clinical study titled "A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV).". The purpose of the study is to learn about the safety and effects of a combined vaccine for RSV and COVID-19 when given with a seasonal flu vaccine or when given alone. A combined vaccine will help to reduce the number of vaccinations given when trying to prevent respiratory infections. This study ...
What is the current status of trial NCT05886777?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,142 participants. The study started on 2023-06-05. Estimated completion is 2024-01-01.
What interventions are being tested in trial NCT05886777?
The interventions under investigation include: RSVpreF (BIOLOGICAL), QIV (BIOLOGICAL), Normal Saline Placebo (BIOLOGICAL), Combination [RSVpreF+BNTb162b2] (BIOLOGICAL), Bivalent BNT162b2 (original/Omi BA.4/BA.5) (BIOLOGICAL).
Who is sponsoring clinical trial NCT05886777?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.